severe asthma, severe allergic asthma, chronic spontaneous urticaria
Respiratory · 2025–2025
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of uncontrolled severe asthma, uncontrolled severe allergic asthma (aged 6 to <12 and ≥12 years), and severe chronic spontaneous urticaria. | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy · Asthma Australia · National Allergy Council · Anaphylaxis Australia |
Who spoke
Australasian Society of Clinical Immunology and Allergy · Asthma Australia · National Allergy Council · Anaphylaxis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.